2843 E. Grand River Avenue – #230 East Lansing, MI 48823 [email protected] 303-783-0924

Leiomyosarcoma Research Updates/About Clinical Trials

leiomyosarcoma research

♦ To view more information, return to the research drop-down menu

Dr. Seth Pollack, a medical oncologist, surgeon, and sarcoma specialist, explains why he is excited about the prospect of immunotherapy in sarcoma treatment.

Dr. Sujana Movva, a medical oncologist, talks about a study in which scientists profiled more than 1900 sarcoma tissue samples to identify potential new treatment techniques.

Dr. William Tap, chief of the Sarcoma Medical Oncology Service, explains how research is leading to the development of new drug treatments that target genetic abnormalities in sarcoma.

September 27, 2016- A panel of leading cancer researchers discuss the effectiveness of Olaratmab, Eribulin Mesylate, and Trabectedin in the treatment of soft tissue sarcomas.

Metastatic Uterine LMS:
Olaratumab for LMS-Dr. Mark Agulnik describes the use of olaratumab for the treatment of uterine leiomyosarcoma (LMS) metastatic to the peritoneum and lungs.

September 7, 2016-The Blue Ribbon Panel report presented to the National Cancer Advisory Board describes 10 research recommendations for achieving the Cancer Moonshot’s goal of making a decade’s worth of progress in cancer prevention, diagnosis, and treatment in just 5 years.

Blue Ribbon Panel Recommendation Topics:

1. Establish a network for direct patient involvement–encourage patients to contribute their comprehensive tumor profile data to expand knowledge about what therapies work, in whom, and in which types of cancer.

2. Create a clinical trials network devoted exclusively to immunotherapy-establish a cancer immunotherapy clinical trials network devoted exclusively to discovering and evaluating immunotherapy approaches.

3. Develop ways to overcome cancer’s resistance to therapy-identify therapeutic targets to overcome drug resistance through studies that determine the mechanisms that lead cancer cells to become resistant to previously effective treatments.

4. Build a national cancer data ecosystem-create a national ecosystem for sharing and analyzing cancer data so that researchers, clinicians, and patients will be able to contribute data, which will facilitate efficient data analysis.

5. Intensify research on the major drivers of childhood cancers-improve our understanding of fusion oncoproteins in pediatric cancer and use new preclinical models to develop inhibitors that target them.

6. Minimize cancer treatment’s debilitating side effects-accelerate the development of guidelines for routine monitoring and management of patient-reported symptoms to minimize debilitating side effects of cancer and its treatment.

7. Expand use of proven cancer prevention and early detection strategies-reduce cancer risk and cancer health disparities through approaches in development, testing, and broad adoption of proven prevention strategies.

8. Mine past patient data to predict future patient outcomes–predict response to standard treatments through retrospective analysis of patient specimens.

9. Develop a 3-D cancer atlas–create dynamic 3-D maps of human tumor evolution to document the genetic lesions and cellular interactions of each tumor as it evolves from a precancerous lesion to advanced cancer.

10. Develop new cancer technologies–develop new enabling cancer technologies to characterize tumors and test therapies.

For more information on the Blue Ribbon Panel report, visit the website below:


About Clinical Trials-


SARC – home website:


SARC – Clinical Trial Listings:


SARC – SARC Centers (Map & list):


Clinical Trials Guidelines

What is a Clinical Trial –    A research study designed  to evaluate new cutting-edge therapies using cancer patients.  Trials provide an important opportunity for  patients  to be part of research efforts evaluating new chemotherapy and immunotherapy drugs/agents,  new radiation therapy techniques,  new surgical techniques, and creative new ways to use different cancer treatments in combination.

Participation in Clinical Trials – It is most important to discuss with your oncologist the possibility of participating in a clinical trial, especially if you did not initially respond or are no longer responding to existing  conventional therapies.

IMPORTANT NOTE:   Before considering whether to participate in a clinical trial, learn as much as possible about the clinical trial,  do as much investigation of the clinical trial as you can on your own. Then ask as many questions as you need to thoroughly understand the pros and cons of participating in the clinical trial.

Suggested Pertinent Questions to Ask Your Oncologist about a Clinical Trial:

  1. Are there any other existing established treatments that I should consider before participating in this or other clinical trials?
  2. What phase trial is this– Phase 1, Phase 2 or Phase 3?
  3. Do I meet the eligibility criteria for the Clinical Trial that I wish to participate in?
  4. What could my participation in the clinical trial mean for me in the short term / long term, based on the nature  of this trial?
  5. Are there known side effects or risks from the treatment I will receive in this clinical trial? If so, what are they?
  6. Where will I receive the treatment — as a hospital inpatient or in an outpatient setting?
  7. Must the treatment only be administered at a participating research center requiring travel to the center?
  8. What is the treatment protocol — number of drugs or agents to be administered, route of administration ( oral or intravenous), length of time for the administration of the treatment, how many courses of the treatment will I receive, and what is the anticipated duration of the trial?
  9. Will there be patients enrolled in the trial who will not receive the drugs or agents being tested (i.e. is this a double-blind clinical trial)?
  10. How will I be monitored during the clinical trial — required blood tests or radiology/imaging studies and their frequency?
  11. Will serial biopsies be required as part of the clinical trial?
  12. Would I be allowed to participate in the next phase of the trial, assuming the trial progresses from the phase of the trial that I am participating in?
  13. Will I receive assistance/guidance on applying for participation in the trial?


  1. PHASE 1 – First step of the research study.  Duration :  6 months – 1 year (approximate). Patient participation:  15 – 20 patients approximately (may vary somewhat). Goal:  to test an experimental drug or treatment in a small group for the first time to evaluate tumor response,  identify side effects, and determine the maximum tolerable dosage.
  1. Phase 2 – Only treatments proven to be safe in Phase 1 studies progress to the Phase 2 stage. Patient participation:  20 – 80  or 100 – 500, depending on the research facility. Duration:  6 months to 1 year or more to complete. Goal:  The experimental drug or treatment is given to a larger group to evaluate its effectiveness and to further assess safety.
  1. Phase 3 –   Progression to apply the study drug or treatment to a larger patient group. Duration:  1 – 4 years to complete depending on the type of cancer, type of study, and number of patient participants.   Again, safety and side effects are well monitored and evaluated by the researchers.  Goal:  To compare a new drug or treatment to other standard treatments currently used to determine which may be most effective to treat the cancer.
  1. Phase 4 –  Post Marketing studies, which are conducted after a treatment is approved by the FDA, provide additional information including the treatment or drug’s risks and best use.

The ClinicalTrials.gov Glossary of Common Site Terms has definitions for terms used on this Web site that may be unfamiliar to you.

To view current clinical trial listings, click here